Trials / Completed
CompletedNCT04355637
Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Sara Varea · Academic / Other
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
Randomized, prospective, controlled open label clinical trial aimed at investigating if the addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a composite variable by the initiation of treatment with high flow-O2 therapy, non-invasive or invasive ventilation, systemic steroids, use of biologics (anti IL-6 or anti IL-1) and/or death) according to hospital standard of care guidance) at day 15 after initiation of therapeutic intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled budesonide | adding budesonide to standard of care for pneumonia in COVID19 positive patients |
Timeline
- Start date
- 2020-04-21
- Primary completion
- 2021-06-30
- Completion
- 2021-06-30
- First posted
- 2020-04-21
- Last updated
- 2021-09-22
Locations
14 sites across 2 countries: Argentina, Spain
Source: ClinicalTrials.gov record NCT04355637. Inclusion in this directory is not an endorsement.